FDA-approved1,2Evidence: Limited human dataNot a peptideHormones · Bone and growth

Mecasermin1,2

Also called Increlex1

Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.

Key takeaway

Mecasermin is recombinant human insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein identical to the body’s own, and the active ingredient in Increlex. At 70 amino acids it is a protein under FDA’s definition, not a peptide.1,3 FDA approved Increlex in 2005 to treat growth failure in children aged 2 and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion and antibodies that block growth hormone.1,2 In five studies of 71 children, growth rate rose from 2.8 cm a year before treatment to 8.0 cm in the first year. The label has no boxed warning but warns of severe low blood sugar.1

Mecasermin at a glance

Substance typeNot a peptide. The Increlex label states that mecasermin is a single chain of 70 amino acids, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,3
What it isHuman IGF-1 made by recombinant DNA technology in bacteria: a single chain of 70 amino acids with three disulfide bridges, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005. The label has no boxed warning.1,2
Human evidenceFive studies in 71 children with severe primary IGF-1 deficiency, four of them open-label, pooled in the label.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is mecasermin?

Mecasermin is human insulin-like growth factor 1 made by recombinant DNA technology in E. coli bacteria. The label states that it is a single chain of 70 amino acids with the same sequence as the body’s own IGF-1.1

FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so mecasermin counts as a protein, not a peptide.1,3

In the United States it is the active ingredient of Increlex, approved under application 021839, according to Drugs@FDA.2

How does mecasermin work?

Growth hormone normally makes the liver and other tissues produce IGF-1, which acts on the type 1 IGF-1 receptor to drive growth in height, according to the label. Mecasermin supplies IGF-1 directly.1

The label states that IGF-1 also has insulin-like effects on glucose uptake, which is why low blood sugar is its main warning.1

What do human studies show?

The label pools five studies, four open-label and one double-blind and placebo-controlled, in 71 children with severe primary IGF-1 deficiency, most of whom had Laron syndrome.1

Mean growth rate was 2.8 cm a year before treatment, 8.0 cm in the first year and 5.8 cm in the second, and remained above the pre-treatment average, by smaller margins, in the children followed for longer.1

What the evidence base contains

  • Small, short, or incompletely reported human study Five clinical studies, four open-label and one double-blind and placebo-controlled, in 71 children with severe primary IGF-1 deficiency, pooled in the label, in which growth rate rose from a mean of 2.8 to 8.0 cm a year in the first year of treatment.1

Evidence-strength label: Limited human data. How this label is assigned

Is mecasermin FDA-approved?

Yes. Drugs@FDA lists Increlex, application 021839, with an original approval date of August 30, 2005.2

The Increlex label cited here (DailyMed SPL version 4, published November 17, 2025) states that it is indicated for growth failure in children 2 years and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone, and that it is not a substitute for growth hormone.1

The label has no boxed warning. It warns that severe low blood sugar, including seizures, has been seen with Increlex, and also warns of serious allergic reactions.1

Timeline

  1. FDA approves Increlex, application 021839, according to Drugs@FDA.2
  2. DailyMed publishes version 4 of the Increlex label, the version cited here.1

What is still unknown?

How it affects final adult height compared with no treatment: most of the label’s studies were open-label and had no untreated comparison group.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Mecasermin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Mecasermin are a bounded selection, not every registration or paper about Mecasermin. For the years before Mecasermin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Mecasermin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Mecasermin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Increlex for severe primary IGF-1 deficiency in children. Approval rests on five studies in 71 children, mostly open-label, in which growth rate rose in the first year of treatment. The label warns of severe low blood sugar.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Mecasermin?

FDA-approved as Increlex for severe primary IGF-1 deficiency in children. Approval rests on five studies in 71 children, mostly open-label, in which growth rate rose in the first year of treatment. The label warns of severe low blood sugar.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
18
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Mecasermin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

32Selected dated records
35Connected citations
18Populated source years1997–2026
3/4Record lanes present

Registered human studies

Trial composition

8 of 9 selected trial records include at least one phase value; 9 of 9 include a status value in the retained structured contract.

PhasesPhase 2 5Not applicable 3Phase 1 3Phase 3 1
Status at observationCompleted 8Recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

18 of 18 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 16Review 8Case Reports 5Letter 2Research Support, Non-U.S. Gov't 2Systematic Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
4
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
32

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 32 dated records

Research hub

Explore the Mecasermin evidence record

Open all 32 records →
32Dated records
3Evidence types
32Cited public sources
18Source years

Change ledger

Recently changed for Mecasermin

Open all 32 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Federal Register notice 97-10541

The Federal Register published notice 97-10541, attributed to FDA and its parent HHS department, on 1997-04-23. Its official title is “Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.

PeptideScanner change date
November 17, 2026
Cited source date
April 23, 1997
Evidence lane
Regulatory
Record added

Federal Register notice 98-7053

The Federal Register published notice 98-7053, attributed to FDA and its parent HHS department, on 1998-03-19. Its official title is “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Mecasermin.

PeptideScanner change date
November 17, 2026
Cited source date
March 19, 1998
Evidence lane
Regulatory

Official-source collections

Source records for Mecasermin

Open the full research atlas →
PubMed18

18 with attributed title, venue, publication-date, and type metadata.

  1. Mecasermin for the treatment of Rett Syndrome: a systematic review.Neurogenetics · 2025 11 01
  2. Mecasermin for primary insulin-like growth factor-1 deficiency.Australian prescriber · 2022 12 01
  3. Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment.Stem cell reviews and reports · 2022 10 21
Explore all selected literature →
ClinicalTrials.gov9

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT00903110Registry update February 6, 2026 · current at observation
  2. NCT02636270Registry update February 28, 2024 · completed at observation
  3. NCT00571727Registry update July 6, 2023 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span April 23, 1997 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3
Dated updates connected to this profile · 32

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Mecasermin for the treatment of Rett Syndrome: a systematic review.↗

    PubMed lists PMID 41174329 in Neurogenetics as Journal Article, Systematic Review, with publication-date metadata of 2025-11-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00903110↗

    PeptideScanner retained ClinicalTrials.gov record NCT00903110 at 2026-11-16T17:35:13.282Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  3. Literature metadata

    Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment.↗

    PubMed lists PMID 36269524 in Stem cell reviews and reports as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02636270↗

    PeptideScanner retained ClinicalTrials.gov record NCT02636270 at 2026-11-16T17:35:13.282Z. Its registry update date was 2024-02-28, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00571727↗

    PeptideScanner retained ClinicalTrials.gov record NCT00571727 at 2026-11-16T17:35:13.282Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  6. Literature metadata

    Mecasermin for primary insulin-like growth factor-1 deficiency.↗

    PubMed lists PMID 36479333 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2022-12-01 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Mecasermin.↗

    PubMed lists PMID 18481900 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, Review, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.↗

    PubMed lists PMID 19707272 in Therapeutics and clinical risk management as Journal Article, with publication-date metadata of 2009-08-03 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00516386↗

    PeptideScanner retained ClinicalTrials.gov record NCT00516386 at 2026-11-16T17:35:13.282Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was mecasermin.↗

  10. Literature metadata

    Efficient process development for high-level production, purification, formulation, and characterization of recombinant mecasermin in Escherichia coli.↗

    PubMed lists PMID 32692415 in Biotechnology and applied biochemistry as Journal Article, with publication-date metadata of 2020-08-07 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.↗

    PubMed lists PMID 29750649 in Journal of pediatric endocrinology & metabolism : JPEM as Case Reports, Journal Article, with publication-date metadata of 2018-06-27 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Recombinant production of mecasermin in E. coli expression system.↗

    PubMed lists PMID 26339260 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2014 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    Definition of the Term “Biological Product” (final rule, February 21, 2020) · FR Doc. 2020-03505 ↗

    Federal Register · Official source · Source checked November 16, 2026